Marinus Pharmaceuticals Inc (NASDAQ:MRNS) reported near-term clinical value catalysts including commencement of Phase 2 study in females suffering with PPD in 1H2017. The company is all set to post data from children with genetic seizure ailments in mid-2017. The SE Phase 2 trial will start in 2H2017.
Christopher M. Cashman, the CEO of Marinus, reported that they have directed their efforts towards indications where they think there is an unmet medical need and seen therapeutic gain from ganaxolone’s GABAA modulation process. The company recently appointed Dr. Lorianne Masuoka as CMO, following which it is focus on strategy and vision to enhance the lives of many patients facing depression, anxiety disorders and seizures.
Recently, the company announced the publication of ganaxolone data in the Neuropharmacology January release demonstrating decline in seizures and improvement in performances in a preclinical mechanism of Angelman syndrome.
Platform presentation of the clinical report from the trial evaluating ganaxolone in adults and children with Fragile X Syndrome. Patients enrolled in this study with a higher anxiety level at baseline showed separation between placebo and ganaxolone in anxiety and positive trends in enhancement in attention and hyperactivity.
Demonstration of ganaxolone Phase I report on Status Epilepticus and Acute Seizures and assortment as a Best Poster for periodical in Epilepsia. The phase I clinical report showed that ganaxolone 4 was safe and well-tolerated and attained targeted dose levels in an interim period of time.
At March 31, 2017, the firm had investments and cash/cash equivalents of more than $24 million versus $30 million at close of December 31, 2016. The cash position is considered as adequate to support operations into 2H2018.
In the last trading session, the stock price of Marinus traded in a narrow range and closed flat at $1.36. The decline came at a share volume of 147,353 compared to average share volume of 165,879.